Piper Sandler Maintains a Buy Rating on Cytokinetics (CYTK) With a $107 PT - MSN
Yesterday • Google News
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating di.
Yesterday • Google News
3 days ago • Google News